Paradoxical effects of antioxidants on cancer

Rejuvenation Research

Volumn 17, Issue 3, 2014, Pages 306-311

  Mendelsohn, Andrew R ^a   Larrick, James W ^a  

^a Panorama Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; B RAF KINASE; FREE RADICAL; HYDROGEN PEROXIDE; K RAS PROTEIN; MYC PROTEIN; PROTEIN P53; REACTIVE OXYGEN METABOLITE; SULFORAPHANE; TRANSCRIPTION FACTOR NRF2;

ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PREVENTION; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOGENESIS; CARCINOGENICITY; CELL PROLIFERATION; CELL STRESS; CLINICAL TRIAL (TOPIC); CYTOTOXICITY; DISEASE COURSE; EXTRACELLULAR FLUID; GENE EXPRESSION; HUMAN; IN VIVO STUDY; LUNG CANCER; NEOPLASM; NONHUMAN; OUTCOME ASSESSMENT; PARADOXICAL DRUG REACTION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHENOTYPE; PRIORITY JOURNAL; REVIEW; RODENT; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; TUMOR VOLUME; CELL TRANSFORMATION; DRUG EFFECTS; PATHOLOGY;

ANTIOXIDANTS; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; NEOPLASMS;

EID: 84902585255     PISSN: 15491684     EISSN: 15578577     Source Type: Journal    
DOI: 10.1089/rej.2014.1577     Document Type: Review

References (38)

1. Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, Keogh JP, Meyskens FL Jr, Valanis B, Williams JH Jr, Barnhart S, Cherniack MG, Brodkin CA, Hammar S. Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial. J Natl Cancer Inst 1996;88:1550-1559. (Pubitemid 26374508)
2. Sayin VI, Ibrahim MX, Larsson E, Nilsson JA, Lindahl P, Bergo MO. Antioxidants accelerate lung cancer progression in mice. Sci Transl Med 2014;6:221ra15.
3. Sablina AA, Budanov AV, Ilyinskaya GV, Agapova LS, Kravchenko JE, Chumakov PM. The antioxidant function of the p53 tumor suppressor. Nat Med 2005;11:1306-1313. (Pubitemid 41752911)
4. Kirshner JR, He S, Balasubramanyam V, Kepros J, Yang C-Y, Zhang M, Du Z, Barsoum J, Bertin J. Elesclomol induces cancer cell apoptosis through oxidative stress. Mol Cancer Ther 2008;7:2319-2327.
5. De Nicola GM, Karreth FA, Humpton TJ, Gopinathan A, Wei C, Frese K, Mangal D, Yu KH, Yeo CJ, Calhoun ES, Scrimieri F, Winter JM, Hruban RH, Iacobuzio-Donahue C, Kern SE, Blair IA, Tuveson DA. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 2011;475:106-109.
6. Cameron E, Pauling L. Supplemental ascorbate in the supportive treatment of cancer: Prolongation of survival times in terminal human cancer. Proc Natl Acad Sci USA 1976;73:3685-3689.
7. Cameron E, Pauling L. Supplemental ascorbate in the supportive treatment of cancer: Reevaluation of prolongation of survival times in terminal human cancer. Proc Natl Acad Sci USA 1978;75:4538-4542. (Pubitemid 9028392)
8. Creagan ET, Moertel CG, O'Fallon JR, Schutt AJ, O'Connell MJ, Rubin J, Frytak S. Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled trial. N Engl J Med 1979; 301:687-690. (Pubitemid 10240445)
9. Moertel CG, Fleming TR, Creagan ET, Rubin J, O'Connell MJ, Ames MM. High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison. N Engl J Med 1985;312:137-141. (Pubitemid 15192859)
10. Padayatty SJ, Riordan HD, Hewitt SM, Katz A, Hoffer LJ, Levine M. Intravenously administered vitamin C as cancer therapy: Three cases. CMAJ Can Med Assoc J 2006;174:937-942.
11. Drisko JA, Chapman J, Hunter VJ. The use of antioxidants with first-line chemotherapy in two cases of ovarian cancer. J Am Coll Nutr 2003;22:118-123. (Pubitemid 36417825)
12. Ma Y, Chapman J, Levine M, Polireddy K, Drisko J, Chen Q. High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy. Sci Transl Med 2014;6:222ra18.
13. Levine M, Conry-Cantilena C, Wang Y, Welch RW, Washko PW, Dhariwal KR, Park JB, Lazarev A, Graumlich JF, King J, Cantilena LR. Vitamin C pharmacokinetics in healthy volunteers: Evidence for a recommended dietary allowance. Proc Natl Acad Sci USA 1996;93:3704-3709. (Pubitemid 26125678)
14. Padayatty SJ, Sun H, Wang Y, Riordan HD, Hewitt SM, Katz A, Wesley RA, Levine M. Vitamin C pharmacokinetics: Implications for oral and intravenous use. Ann Intern Med 2004;140:533-537.
15. Chen Q, Espey MG, Krishna MC, Mitchell JB, Corpe CP, Buettner GR, Shacter E, Levine M. Pharmacologic ascorbic acid concentrations selectively kill cancer cells: Action as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci USA 2005;102:13604-13609. (Pubitemid 41420895)
16. Chen Q, Espey MG, Sun AY, Lee J-H, Krishna MC, Shacter E, Choyke PL, Pooput C, Kirk KL, Buettner GR, Levine M. Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo. Proc Natl Acad Sci USA 2007;104:8749-8754. (Pubitemid 47175383)
17. Chen Q, Espey MG, Sun AY, Pooput C, Kirk KL, Krishna MC, Khosh DB, Drisko J, Levine M. Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proc Natl Acad Sci USA 2008;105:11105-11109.
18. Du J, Martin SM, Levine M, Wagner BA, Buettner GR, Wang S, Taghiyev AF, Du C, Knudson CM, Cullen JJ. Mechanisms of ascorbate-induced cytotoxicity in pancreatic cancer. Clin Cancer Res 2010;16:509-520.
19. Verrax J, Delvaux M, Beghein N, Taper H, Gallez B, Buc Calderon P. Enhancement of quinone redox cycling by ascorbate induces a caspase-3 independent cell death in human leukaemia cells. An in vitro comparative study. Free Radic Res 2005;39:649-657. (Pubitemid 40846837)
20. Chen P, Yu J, Chalmers B, Drisko J, Yang J, Li B, Chen Q. Pharmacological ascorbate induces cytotoxicity in prostate cancer cells through ATP depletion and induction of autophagy. Anticancer Drugs 2012;23:437-444.
21. Alexander A, Cai S-L, Kim J, Nanez A, Sahin M, MacLean KH, Inoki K, Guan KL, Shen J, Person MD, Kusewitt D, Mills GB, Kastan MB, Walker CL. ATM signals to TSC2 in the cytoplasm to regulate mTORC1 in response to ROS. Proc Natl Acad Sci USA 2010;107:4153-4158.
22. Alexander A, Kim J, Walker CL. ATM engages the TSC2/mTORC1 signaling node to regulate autophagy. Autophagy 2010;6:672-673.
23. Chou T-C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006;58:621-681. (Pubitemid 44403686)
24. Stephenson CM, Levin RD, Spector T, Lis CG. Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with advanced cancer. Cancer Chemother Pharmacol 2013;72:139-146.
25. Hoffer LJ, Levine M, Assouline S, Melnychuk D, Padayatty SJ, Rosadiuk K, Rousseau C, Robitaille L, Miller WH Jr. Phase I clinical trial of i.v. ascorbic acid in advanced malignancy. Ann Oncol 2008;19:1969-1974.
26. Bjelakovic G, Nikolova D, Simonetti RG, Gluud C. Systematic review: primary and secondary prevention of gastrointestinal cancers with antioxidant supplements. Aliment Pharmacol Ther 2008;28:689-703.
27. Bjelakovic G, Nikolova D, Gluud C. Antioxidant supplements and mortality. Curr Opin Clin Nutr Metab Care 2014;17:40-44.
28. Watson J. Oxidants, antioxidants and the current incurability of metastatic cancers. Open Biol 2013;3:120144.
29. Ramos-Gomez M, Kwak M-K, Dolan PM, Itoh K, Yamamoto M, Talalay P, Kensler TW. Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice. Proc Natl Acad Sci USA 2001;98:3410-3415. (Pubitemid 32220859)
30. Iida K, Itoh K, Kumagai Y, Oyasu R, Hattori K, Kawai K, Shimazui T, Akaza H, Yamamoto M. Nrf2 is essential for the chemopreventive efficacy of oltipraz against urinary bladder carcinogenesis. Cancer Res 2004;64:6424-6431. (Pubitemid 39297896)
31. Rotblat B, Melino G, Knight RA. NRF2 and p53: Januses in cancer? Oncotarget 2012;3:1272-1283.
32. Bertheau P, Turpin E, Rickman DS, Espié M, de Reyniès A, Feugeas J-P, Plassa LF, Soliman H, Varna M, de Roquancourt A, Lehmann-Che J, Beuzard Y, Marty M, Misset JL, Janin A, de Thé H. Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin- cyclophosphamide regimen. PLoS Med 2007;4:e90.
33. Jackson JG, Pant V, Li Q, Chang LL, Quintás-Cardama A, Garza D, Tavana O, Yang P, Manshouri T, Li Y, El-Naggar AK, Lozano G. p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer. Cancer Cell 2012;21:793-806.
34. Sinthupibulyakit C, Ittarat W, St Clair WH, St Clair DK. p53 Protects lung cancer cells against metabolic stress. Int J Oncol 2010;37:1575-1581.
35. Ristow M, Zarse K, Oberbach A, Klöting N, Birringer M, Kiehntopf M, Stumvoll M, Kahn CR, Blüher M. Antioxidants prevent health-promoting effects of physical exercise in humans. Proc Natl Acad Sci USA 2009;106:8665-8670.
36. Gibney GT, Messina JL, Fedorenko IV, Sondak VK, Smalley KSM. Paradoxical oncogenesis and the long term consequences of BRAF inhibition in melanoma. Nat Rev Clin Oncol 2013;10:390-399.
37. Phoenix KN, Vumbaca F, Claffey KP. Therapeutic metformin/ampk activation promotes the angiogenic phenotype in the ER-negative MDA-MB-435 breast cancer model. Breast Cancer Res Treat 2009;113:101-111.
38. Martin MJ, Hayward R, Viros A, Marais R. Metformin accelerates the growth of BRAFV600E-driven melanoma by upregulating VEGF-A. Cancer Discov 2012;2:344-355.